A Leap Towards Radical Human Life Extension: The Unusual Clinical Trial
In the realm of biotechnology, a groundbreaking clinical trial is about to unfold, promising to push the boundaries of human longevity. This trial, led by Unlimited Bio, a biotech company based in Prspera, Honduras, aims to inject a handful of volunteers with two experimental gene therapies. The goal: to achieve radical human life extension.
The Quest for Longevity Therapies
The two gene therapies under trial are designed to enhance blood supply to muscles and support muscle growth. The company behind the trial, Unlimited Bio, believes these therapies could lead to improvements in strength, endurance, and recovery.
Ethical Concerns and Regulatory Loopholes
However, some experts have raised concerns about the trial, questioning the safety and efficacy of giving multiple gene therapies to small numbers of healthy individuals. They argue that it will be impossible to draw firm conclusions from such a small study and that the trial will not reveal anything about longevity.
Longevity Tourism in the North East and India
The biohacking community, including celebrities like Khloe Kardashian and Dave Asprey, have already shown interest in these therapies. Asprey, a biohacking influencer, has publicly stated his intention to live to 180 and has already received one of the therapies in Mexico. This trend of "longevity tourism" could potentially attract individuals from North East India and other parts of the country seeking life extension treatments.
Implications for the Future of Gene Therapy
The trial by Unlimited Bio is part of a broader trend of companies exploring gene therapies for healthy individuals. One such company, Minicircle, developed a gene therapy to increase production of follistatin, a protein involved in muscle growth. This treatment is already available at a clinic in Prspera, Honduras, for a reported price of $25,000.
The developments in gene therapies for longevity could have significant implications for the North East region and India, as they may attract investments in biotech and health tourism. However, it is crucial to ensure that these treatments are safe, effective, and regulated to protect the public interest.
A Forward Look
As we stand on the precipice of a new era in human life extension, it is essential to approach these developments with caution and critical analysis. While the potential benefits are tantalizing, the risks and uncertainties cannot be ignored. As more companies venture into this uncharted territory, it is incumbent upon us to scrutinize their claims, ensure ethical conduct, and prioritize public safety.